← Back to Clinical Trials
Recruiting NCT06867926

NCT06867926 The Effect of Cardiac Rehabilitation on Oxidative DNA Damage and Inflammation in Patients With Coronary Artery Disease

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06867926
Status Recruiting
Phase
Sponsor TC Erciyes University
Condition Coronary Arterial Disease (CAD)
Study Type INTERVENTIONAL
Enrollment 70 participants
Start Date 2025-05-15
Primary Completion 2025-07-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
Cardiac rehabilitation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 70 participants in total. It began in 2025-05-15 with a primary completion date of 2025-07-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The objective of this study was to determine the levels of 8-hydroxy-2'-deoxyguanosine (8-OHdG), an indicator of oxidative stress, and to demonstrate oxidative DNA damage in cardiac rehabilitation treatment in patients with coronary artery disease. Additionally, proinflammatory cytokines TNFα, IL-1β, and IL-6 levels were measured to evaluate the significance of cardiac rehabilitation treatment in patients with coronary artery disease and to assess the correlation between cytokine levels and 8-OHdG levels.

Eligibility Criteria

Inclusion Criteria: Inclusion Criteria for Patient Volunteers 1. Patients aged 18-65 years with a diagnosis of coronary artery disease and no contraindications to cardiac rehabilitation and exercise testing 2. Patients who will undergo cardiopulmonary exercise testing before cardiac rehabilitation 3. Patients whose cognitive status is sufficient to complete the study and who can cooperate Inclusion Criteria for Healthy Volunteers 1. 18 years of age or older 2. Not having a chronic disease (such as uncontrolled diabetes mellitus, hypertension, heart and kidney failure) 3. Not taking regular medication Exclusion Criteria: Exclusion Criteria for Patient Volunteers 1. Having heart failure 2. Unstable Angina Pectoris 3. Complex ventricular arrhythmia 4. Having a pacemaker 5. Having orthopedic or neurological diseases that prevent exercise 6. Having kidney-liver disease 7. Exercise is contraindicated 8. History of inflammatory diseases 9. Having a history of cancer-immunologic disease Exclusion Criteria for Healthy Volunteers 1. Having a history of chronic diseases such as diabetes mellitus, hypertension, heart and kidney failure 2. Being on regular medication for the last 6 months 3. being under 18 years of age

Contact & Investigator

Central Contact

Hasan KARA, M.D.

✉ drhasankara@yandex.com

📞 +905552592665

Frequently Asked Questions

Who can join the NCT06867926 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Coronary Arterial Disease (CAD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06867926 currently recruiting?

Yes, NCT06867926 is actively recruiting participants. Contact the research team at drhasankara@yandex.com for enrollment information.

Where is the NCT06867926 trial being conducted?

This trial is being conducted at Kayseri, Turkey (Türkiye).

Who is sponsoring the NCT06867926 clinical trial?

NCT06867926 is sponsored by TC Erciyes University. The trial plans to enroll 70 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology